Sickle Cell Disease

This year’s virtual ASH Annual Meeting and Exposition featured hundreds of abstracts that spotlighted research advances in blood cancer and benign hematology research.

The use of gene-edited stem cells has shown early positive results among patients with sickle cell disease and transfusion-dependent beta-thalassemia, according to data presented at the virtual ASH Annual Meeting and Exposition.

Patients with sickle cell disease may be at higher risk for certain COVID-19 complications and death, according to results of two studies presented at ASH Annual Meeting and Exposition.

Toxicity on spermatogenesis may not be a major concern for boys with severe sickle cell disease who require hydroxyurea treatment before puberty, according to results of a study published in Blood.

The FDA granted orphan drug designation to CSL889 for the treatment of sickle cell disease, according to the agent’s manufacturer.

Pain is one of the most common symptoms of sickle cell disease, and severe pain is the leading cause of ED visits and hospital stays among patients with this disease.

September is National Sickle Cell Awareness Month.

The FDA granted rare pediatric disease designation to EDIT-301, an investigational autologous cell therapy for the treatment of sickle cell disease, according to the agent’s manufacturer.

Receiving medical marijuana appeared associated with reduced hospital admission rates among patients with sickle cell disease, according to results of a retrospective study published in Blood Advances.

Vaporized cannabis did not significantly reduce chronic pain and most associated symptoms compared with placebo among adults with sickle cell disease, according to results of a randomized study published in JAMA Network Open.